Pfizer Inc announced that a phase 3 study to assess the use of Lyrica (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic─clonic (PGTC) seizures did not meet its primary endpoint.
Ook interessant voor je
